317 related articles for article (PubMed ID: 12352242)
1. Asymptomatic colorectal neoplasia and fecal characteristics: a case-control study of subjects participating in the nottingham fecal occult blood screening trial.
Little J; Owen RW; Fernandez F; Hawtin PG; Hill MJ; Logan RF; Thompson MH; Hardcastle JD
Dis Colon Rectum; 2002 Sep; 45(9):1233-41. PubMed ID: 12352242
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
3. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
4. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history.
Rex DK; Lehman GA; Ulbright TM; Smith JJ; Pound DC; Hawes RH; Helper DJ; Wiersema MJ; Langefeld CD; Li W
Am J Gastroenterol; 1993 Jun; 88(6):825-31. PubMed ID: 8503374
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of immunochemical fecal occult blood test for small colorectal neoplasms.
Abdul Fattah AS; Nakama H; Zhang B; Uehara Y; Kamijo N; Fujimori K
Eur J Med Res; 1997 May; 2(5):227-30. PubMed ID: 9153349
[TBL] [Abstract][Full Text] [Related]
6. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
8. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
9. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
[TBL] [Abstract][Full Text] [Related]
10. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of bile acids in the feces of colorectal cancer patients by gas chromatography-mass spectrometry (GC-MS).
Tadano T; Kanoh M; Kondoh H; Matsumoto M; Mimura K; Kanoh Y; Sakamoto K; Kamano T
Rinsho Byori; 2007 May; 55(5):417-27. PubMed ID: 17593686
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the sensitivity of an immunochemical fecal occult blood test for colorectal neoplasia.
Yoshinaga M; Motomura S; Takeda H; Yanagisawa Z; Ikeda K
Am J Gastroenterol; 1995 Jul; 90(7):1076-9. PubMed ID: 7611200
[TBL] [Abstract][Full Text] [Related]
13. [Comparison between application of fecal occult blood quantitive testing instrument and colloidal gold strip method in colorectal cancer screening].
Huang YQ; Zhang MW; Shen YZ; Ma HQ; Cai SR; Zhang SZ; Zheng S
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Aug; 47(8):747-51. PubMed ID: 24246083
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan.
Lee KJ; Inoue M; Otani T; Iwasaki M; Sasazuki S; Tsugane S;
Cancer Detect Prev; 2007; 31(1):3-11. PubMed ID: 17289293
[TBL] [Abstract][Full Text] [Related]
15. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
[TBL] [Abstract][Full Text] [Related]
16. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
17. Fecal occult blood test performance indicators in warfarin-treated patients.
Kershenbaum A; Lavi I; Rennert G; Almog R
Dis Colon Rectum; 2010 Feb; 53(2):224-9. PubMed ID: 20087099
[TBL] [Abstract][Full Text] [Related]
18. Colon cancer screening strategies.
Agrawal J; Syngal S
Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
[TBL] [Abstract][Full Text] [Related]
19. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
Faivre J; Tazi MA; El Mrini T; Lejeune C; Benhamiche AM; Dassonville F
Br J Cancer; 1999 Feb; 79(3-4):680-3. PubMed ID: 10027349
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of mass screening for colorectal cancer with 'sequential fecal occult blood test' in an asymptomatic population. Multicenter GI Research Group of Beijing Area of PLA].
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):230-3. PubMed ID: 8261874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
